Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

Diane E. Milenic(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Steven W. Dodd, Marc Whitlow, James F. Wood, David Filpula, Malcolm Finkelman, P. Snoy, Takashi Yokota

PubMed

December 1, 1991

Cited by 340

Related Papers

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

|The Journal of Experimental Medicine|2006|1.7k

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

|Journal of Clinical Oncology|2010|973

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

|Blood|2005|896

Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors

|Hybridoma|1984|580

A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

|Proceedings of the National Academy of Sciences|1981|563